Molecular Tumor Board Series 2020: Part I

Molecular Tumor Board Series 2020: Part I is organized by Cancer Treatment Centers of America® (CTCA).

Released: March 13, 2020
Expires: March 13, 2021

Target Audience:
Physicians or other clinicians who particpate in molecular tumor boards.

Accreditation:
AMA PRA Category 1 Credit ^TM:
The Morehouse School of Medicine designated this enduring activity for a maximum of up to 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent to their participation in the activity.

Program Description:
A multidisciplinary team discusses treatment options for cancer patients in a tumor board format based on data collected from patients, such as, genetic/genomic testing, pathology and radiological imaging. Cases discussed include: gallbladder carcinoma, triple negative breast cancer, endometrial cancer and adenocarcinoma of unknown primary.

Educational Objectives:
Upon completion of this activity, participants will be able to:
• Describe the necessary components of an effective molecular tumor board
• Explain how to integrate genomic profiling into oncology treatment plans